Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers
BALTIMORE, Jan. 12, 2021 /PRNewswire/ -- Delfi Diagnostics, Inc., a pioneering developer of a new class of high performance, affordable liquid...